Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1308

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 13
Chunk 1308
---
 ratio
was based on the Series B Certificate of Designations and reflected the applicable Alternate Conversion Price.

F-32

During the period from January
1, 2025 to April 10, 2025, the Company sold 290,618 shares of Common Stock of the Company pursuant to the New Keystone Purchase Agreement
for net proceeds of $1,227,242.

On February 5, 2025, the
Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member
of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 2,551,020 shares of its
common stock, par value $0.0001 per share (the “Common Stock”) or common stock equivalents in lieu thereof; and (ii) common
warrants to purchase up to 2,551,020 shares of common stock (the “Warrants”), at a combined public offering price of $1.96
per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase agreement
(the “SPA”) with the investors. The SPA contains customary representations, warranties and agreements of the Company and each
investor and customary indemnification rights and obligations of the parties. In connection with this offering, the Company received net
proceeds of approximately $4.5 million. From January 1, 2025 to April 11, 2025, the Company issued 2,335,280 shares of its common stock
of the aggregate amount of shares of 2,551,020 shares sold. The remaining 215,740 common shares are issuable.

The Warrants have an exercise
price of $1.96 per share, will be immediately exercisable upon stockholder approval and will have a term of exercise equal to five years
following date of the initial exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject
to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock
and the exercise price.

In connection with the Offering,
on February 5, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance
Global Partners (“A.G.P.”), as the exclusive placement agent in connection with the Offering (the “Placement Agent”).
Purs